Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK
Bricanyl Injection, 0.5 mg/ml, solution for injection or infusion.
| Pharmaceutical Form |
|---|
|
Solution for injection or infusion. A clear aqueous solution. |
1 ml solution for injection contains 0.5mg of terbutaline sulfate.
Excipient(s) with known effect: 1 ml also contains sodium (<1 mmol/ml), as sodium chloride.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Terbutaline |
Terbutaline is a selective beta2-adrenoceptor agonist, thus producing relaxation of bronchial smooth muscle, inhibition of the release of endogenous spasmogens, inhibitions of oedema caused by endogenous mediators, increased mucociliary clearance and relaxation of the uterine muscle. |
| List of Excipients |
|---|
|
Sodium chloride |
Packs of 5 × 1ml glass ampoules.
Packs of 10 × 5ml glass ampoules.
Not all pack sizes may be marketed.
AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK
PL 17901/0112
7th May 2002 / 12th May 2007
| Drug | Countries | |
|---|---|---|
| BRICANYL | Austria, Australia, Brazil, Canada, Estonia, Finland, France, Hong Kong, Ireland, Japan, Malta, Netherlands, New Zealand, Tunisia, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
